RecruitingPhase 1NCT07247110

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors

Sponsor

Merck Sharp & Dohme LLC

Enrollment

250 participants

Start Date

Dec 16, 2025

Study Type

INTERVENTIONAL

Conditions

Malignant Neoplasm

Summary

Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Cetuximab, a drug called MK-4716, and others for people with malignant neoplasm. The study is currently recruiting participants at 19 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMK-4716

Oral administration

BIOLOGICALPembrolizumab

Intravenous administration

BIOLOGICALCetuximab

Intravenous administration

Locations(21)

Rutgers Cancer Institute of New Jersey ( Site 0052)

New Brunswick, New Jersey, United States

NEXT Oncology ( Site 0051)

Irving, Texas, United States

NEXT Virginia ( Site 0054)

Fairfax, Virginia, United States

Blacktown Hospital ( Site 0455)

Sydney, New South Wales, Australia

Monash Health ( Site 0452)

Clayton, Victoria, Australia

The Alfred Hospital ( Site 0453)

Melbourne, Victoria, Australia

One Clinical Research ( Site 0454)

Nedlands, Western Australia, Australia

Princess Margaret Cancer Centre ( Site 0001)

Toronto, Ontario, Canada

Centre Hospitalier de l'Université de Montréal ( Site 0003)

Montreal, Quebec, Canada

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0002)

Québec, Quebec, Canada

FALP-UIDO ( Site 0101)

Santiago, Region M. de Santiago, Chile

Pontificia Universidad Catolica de Chile-CICUC ( Site 0103)

Santiago, Region M. de Santiago, Chile

Bradfordhill ( Site 0102)

Santiago, Region M. de Santiago, Chile

Rambam Health Care Campus ( Site 0252)

Haifa, Israel

Rabin Medical Center ( Site 0253)

Petah Tikva, Israel

Sheba Medical Center ( Site 0251)

Ramat Gan, Israel

Seoul National University Hospital ( Site 0501)

Seoul, South Korea

Asan Medical Center ( Site 0502)

Seoul, South Korea

Hospital General Universitari Vall d Hebron ( Site 0360)

Barcelona, Spain

Hospital Clinic de Barcelona ( Site 0362)

Barcelona, Spain

Hospital Universitario Fundacion Jimenez Diaz ( Site 0361)

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07247110

Related Trials

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

NCT0763097417 locations

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT0681864349 locations

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

NCT024796981 location

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

NCT076007496 locations

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

NCT0725273938 locations